This trial is being conducted as a possible treatment for lung cancer with a specific change
in the KRAS gene.
The drugs involved in this study are:
This research study is a Phase I/II clinical trial. Participants are being asked to
participate in the Phase I portion of the study. A Phase I clinical trial tests the safety of
an investigational intervention and also tries to define the appropriate dose of the
investigational intervention to use for further studies. "Investigational" means that the
intervention is being studied.
Palbociclib is an oral drug which has been shown to stop the cell cycle, which is the way a
cell initiates growth. Binimetinib is also an oral drug which stops a signal that a cell
receives, instructing it to grow. By putting these two drugs together the investigators hope
that it will have a greater affect on cancer growth than either drug alone. The FDA (the U.S.
Food and Drug Administration) has not approved binimetinib as a treatment for any disease.
The FDA has not approved palbociclib for use in lung cancer but it has been approved for
other cancer types.
The purpose of this study is to:
Test the combination of these two drugs, Palbociclib and Binimetinib, in order to
determine a safe and tolerable dose of the combination
Determine the response rate of the combination
Further evaluate the safety and side effect profile for the combination of palbociclib
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.